What is Dermata Therapeutics, Inc.'s earnings per share (EPS)?

Dermata Therapeutics, Inc. (DRMA) reported diluted earnings per share of -$8.16 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Dermata Therapeutics, Inc. (DRMA) Financials

DRMA

FY2025 annual

Revenue Not reported for FY2025

Net Income -$7.6M +38.5% YoY

EPS (Diluted) -$8.16 YoY not available

Operating Cash Flow -$7.8M +30.1% YoY

Market Cap $4.3M as of Oct 20, 2026

Price / Sales n/m no revenue reported

Price / Earnings n/m net loss, so no earnings multiple, FY2025

Price / Book 1.2x on $3.5M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 20, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 11, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 11, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the DRMA SEC filings page.

This page shows Dermata Therapeutics, Inc. (DRMA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI DRMA FY2025 2026-10-04

The business remains development-focused: losses consume cash, while 2025 financing rebuilt assets after a sharp balance-sheet contraction.

In FY2025, the company recorded a net loss of $7.6M alongside operating cash flow of -$7.8M, showing that reported earnings closely tracked cash consumption rather than being heavily distorted by non-cash items. That alignment differs from FY2024’s wider asset contraction and indicates the latest improvement in losses did not yet change the underlying cash-funded development model.

The financing inflow of $12.1M exceeded the $7.8M operating cash outflow, so the FY2025 balance-sheet recovery was externally financed rather than produced by operations. Reported cash and investments equaled 11.6 months of the latest annual operating outflow, a balance comparison—not evidence of internally funded operations.

Debt-to-equity fell from 1.3x in FY2024 to 0.3x in FY2025, indicating a materially different balance-sheet posture after financing activity. Meanwhile, R&D fell to $2.9M from $8.2M, so the lower loss reflects reduced development spending rather than demonstrated commercial scale.

Financial Health Signals

Financial health score not available

Dermata Therapeutics, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

2/5

Dermata Therapeutics, Inc. passes 2 of 5 computable financial strength tests (4 of the nine could not be computed from available data). 1 of 4 profitability signals pass, all 1 leverage/liquidity signals pass.

Earnings Quality No Cash Backing

N/A

Dermata Therapeutics, Inc. reported a net loss of $7.6M while operations used $7.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Net Income

-$3.0M

YoY-74.4%

QoQ-60.6%

Dermata Therapeutics, Inc. reported -$3.0M in net income in Q2 2026. This represents a decrease of 74.4% from the same quarter a year earlier. Against the prior quarter it is down 60.6%.

EPS (Diluted)

-$0.74

QoQ-54.2%

Dermata Therapeutics, Inc. earned -$0.74 per diluted share (EPS) in Q2 2026. Against the prior quarter it is down 54.2%.

Revenue

Not reported for Q2 2026.

EBITDA

Not reported for Q2 2026.

Cash & Balance Sheet

Cash & Debt

$4.4M

YoY-31.9%

QoQ-36.5%

5Y CAGR+59.5%

Dermata Therapeutics, Inc. held $4.4M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

QoQ0.0%

5Y CAGR-13.5%

Dermata Therapeutics, Inc. had 4M shares outstanding in Q2 2026. It is unchanged from the prior quarter.

Free Cash Flow

Not reported for Q2 2026.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Return on Equity

-85.1%

YoY-54.8pp

QoQ-56.3pp

Dermata Therapeutics, Inc.'s ROE was -85.1% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 54.8 percentage points from the same quarter a year earlier. Against the prior quarter it is down 56.3 percentage points.

Gross Margin

Not reported for Q2 2026.

Operating Margin

Not reported for Q2 2026.

Net Margin

Not reported for Q2 2026.

Capital Allocation

R&D Spending

$213K

YoY-65.6%

QoQ-44.6%

Dermata Therapeutics, Inc. invested $213K in research and development in Q2 2026. This represents a decrease of 65.6% from the same quarter a year earlier. Against the prior quarter it is down 44.6%.

Share Buybacks

Not reported for Q2 2026.

Capital Expenditures

Not reported for Q2 2026.

DRMA Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

DRMA quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K
R&D Expenses	N/A	$2.9M-64.3%	$8.2M+101.6%	$4.1M-28.0%	$5.7M+63.4%	$3.5M+115.2%	$1.6M
SG&A Expenses	N/A	$4.8M+12.4%	$4.3M+8.5%	$4.0M-1.3%	$4.0M-8.5%	$4.4M+181.0%	$1.6M
Operating Income	N/A	-$7.8M+37.9%	-$12.5M-55.6%	-$8.0M+16.9%	-$9.7M-23.1%	-$7.9M	N/A
EBITDA	N/A	N/A	N/A	N/A	N/A	-$7.9M	N/A
Interest Expense	N/A	N/A	N/A	N/A	$64K+39.4%	$46K-76.9%	$197K
Income Tax	N/A	N/A	$0	$0	$0	$0	$0
Net Income	N/A	-$7.6M+38.5%	-$12.3M-57.6%	-$7.8M+18.9%	-$9.6M-21.6%	-$7.9M	N/A
EPS (Basic)	N/A	-$8.16+89.8%	-$80.32-100.9%	-$39.99-187.3%	-$13.92-472.8%	-$2.43-43.8%	-$1.69
EPS (Diluted)	—	-$8.16	-$80.32-100.9%	-$39.99	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	926,192	152,974-21.5%	194,928	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
R&D Expenses	$213K-65.6%	$384K-70.0%	N/A	$504K-79.0%	$618K-69.2%	$1.3M-20.0%	N/A	$2.4M+165.9%
SG&A Expenses	$2.8M+142.5%	$1.5M+45.7%	N/A	$1.3M+52.4%	$1.2M+32.0%	$1.1M-33.9%	N/A	$824K-9.3%
Operating Income	-$3.0M-70.0%	-$1.9M+17.7%	N/A	-$1.8M+45.4%	-$1.8M+38.5%	-$2.3M+27.0%	N/A	-$3.2M-78.0%
Net Income	-$3.0M-74.4%	-$1.8M+19.8%	N/A	-$1.7M+46.7%	-$1.7M+39.9%	-$2.3M+26.5%	N/A	-$3.2M-84.6%
EPS (Basic)	-$0.74+39.3%	-$0.48+89.3%	-$1.52-107.0%	-$1.65+91.9%	-$1.22+97.1%	-$4.47+36.7%	$21.86+10509.5%	-$20.41-3679.6%
EPS (Diluted)	-$0.74	-$0.48	-$1.52-107.0%	-$1.65	-$1.66	-$4.47+36.7%	$21.86	-$20.41
Diluted Shares (Avg)	4M	4M	N/A	1M	1M	515,465+16.1%	N/A	155,465

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, EBITDA, Interest Expense, Income Tax.

DRMA Balance Sheet

DRMA quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K
Total Assets	$7.9M+122.5%	$3.5M-55.7%	$8.0M+14.9%	$6.9M-40.3%	$11.6M+1819.9%	$605K
Current Assets	$7.9M	N/A	N/A	N/A	$11.6M+1819.9%	$605K
Cash & Equivalents	$7.5M+137.9%	$3.2M-57.5%	$7.4M+19.2%	$6.2M-42.2%	$10.8M+1936.0%	$530K
Short-Term Investments	$0	$0	$0	$0	$0	$0
Long-Term Investments	$0	$0	$0	$0	$0	$0
Total Liabilities	$1.6M-16.8%	$2.0M+21.5%	$1.6M+76.0%	$923K-39.2%	$1.5M-59.9%	$3.8M
Current Liabilities	N/A	N/A	N/A	N/A	$1.5M-59.9%	$3.8M
Non-Current Liabilities	N/A	N/A	N/A	N/A	$0	$0
Total Equity	$6.2M+298.7%	$1.6M-75.4%	$6.4M+5.5%	$6.0M-40.4%	$10.1M+418.0%	-$3.2M
Retained Earnings	-$73.2M-11.5%	-$65.7M-23.0%	-$53.4M-17.1%	-$45.6M-26.7%	-$36.0M-28.1%	-$28.1M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$5.3M-19.9%	$7.5M-25.4%	$7.9M+122.5%	$5.1M-24.2%	$6.6M+26.8%	$10.0M+93.2%	$3.5M-55.7%	$6.7M-8.7%
Current Assets	$5.2M	N/A	$7.9M	N/A	N/A	N/A	N/A	N/A
Cash & Equivalents	$4.4M-31.9%	$6.9M-28.5%	$7.5M+137.9%	$4.7M-24.1%	$6.5M+31.0%	$9.7M+105.3%	$3.2M-57.5%	$6.1M-7.4%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$150K	$93K	N/A	N/A	N/A	N/A	N/A	N/A
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$1.8M+78.6%	$1.1M-61.1%	$1.6M-16.8%	$1.1M-42.9%	$1.0M-46.5%	$2.7M+97.1%	$2.0M+21.5%	$1.9M+112.3%
Total Equity	$3.5M-37.9%	$6.4M-12.2%	$6.2M+298.7%	$4.0M-16.5%	$5.6M+69.2%	$7.3M+91.7%	$1.6M-75.4%	$4.7M-26.0%
Retained Earnings	-$78.0M-12.0%	-$75.1M-10.4%	-$73.2M-11.5%	-$71.4M-14.2%	-$69.7M-17.4%	-$68.0M-20.3%	-$65.7M-23.0%	-$62.5M-22.0%

Not reported in any period shown, so not listed: Accounts Receivable, Goodwill, Current Liabilities, Non-Current Liabilities, Long-Term Debt.

DRMA Cash Flow Statement

DRMA quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K
Operating Cash Flow	-$8.1M	-$7.8M+30.1%	-$11.2M-74.2%	-$6.4M+27.5%	-$8.8M-55.2%	-$5.7M	N/A
Depreciation & Amortization	N/A	N/A	N/A	N/A	N/A	$0-100.0%	$322
Stock-Based Compensation	N/A	$144K-78.1%	$658K+26.0%	$522K-43.9%	$930K-51.2%	$1.9M	$0
Financing Cash Flow	$6.1M	$12.1M+76.0%	$6.9M-9.5%	$7.6M+77.8%	$4.3M-73.2%	$16.0M+521.8%	$2.6M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$2.4M+10.0%	-$2.5M-28.2%	-$1.4M+52.9%	-$1.8M+47.2%	-$2.7M-26.6%	-$1.9M+28.5%	-$2.9M-154.0%	-$3.4M-93.0%
Stock-Based Compensation	$42K+6.5%	$43K+16.4%	N/A	$38K+80.3%	$39K+100.1%	$37K-93.7%	N/A	$21K
Financing Cash Flow	-$323+99.9%	$1.9M-77.6%	$4.2M+6206.4%	-$13K-100.3%	-$548K-123.4%	$8.5M	-$69K-103.5%	$4.6M+13131.4%

Not reported in any period shown, so not listed: Depreciation & Amortization, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.

DRMA Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

DRMA quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K
Return on Equity	-121.4%+665.7pp	-787.1%-664.5pp	-122.6%+37.0pp	-159.6%-81.4pp	-78.2%	N/A
Return on Assets	-96.1%+251.6pp	-347.7%-250.0pp	-97.7%+40.7pp	-138.4%-70.4pp	-68.0%	N/A
Current Ratio	N/A	N/A	N/A	N/A	7.66+7.5x	0.16
Debt-to-Equity	0.26-1.0x	1.26+1.0x	0.26+0.1x	0.150.0x	0.15	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Return on Equity	-85.1%-54.8pp	-28.8%+2.7pp	N/A	-42.7%+24.2pp	-30.3%+55.0pp	-31.6%+50.8pp	N/A	-66.9%-40.1pp
Return on Assets	-55.8%-30.1pp	-24.8%-1.7pp	N/A	-33.4%+14.1pp	-25.6%+28.4pp	-23.0%+37.5pp	N/A	-47.4%-24.0pp
Debt-to-Equity	0.53+0.3x	0.16-0.2x	0.26-1.0x	0.28-0.1x	0.18-0.4x	0.370.0x	1.26+1.0x	0.41+0.3x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Current Ratio, Asset Turnover, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Dermata Therapeutics, Inc. DRMA	FY2025	N/A	-$7.6M	N/A	$4.3M	—
Entero Therapeutics, Inc. ENTO	FY2025	$36K	-$6.4M	N/A	$4.7M	—
Silexion Therapeutics Corp SLXN	FY2025	$155K	-$11.9M	N/A	$2.2M	—
Theriva Biologics, Inc. TOVX	FY2025	N/A	-$23.7M	N/A	$9.4M	—
Galecto, Inc. GLTO	FY2025	N/A	-$209.8M	N/A	$1.7B	—

Where Dermata Therapeutics, Inc. Ranks

Frequently Asked Questions

Is Dermata Therapeutics, Inc. profitable?

No, Dermata Therapeutics, Inc. (DRMA) reported a net income of -$7.6M in fiscal year 2025.

What is Dermata Therapeutics, Inc.'s return on equity (ROE)?

Dermata Therapeutics, Inc. (DRMA) has a return on equity of -121.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Dermata Therapeutics, Inc.'s operating cash flow?

Dermata Therapeutics, Inc. (DRMA) recorded an outflow of $7.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Dermata Therapeutics, Inc.'s total assets?

Dermata Therapeutics, Inc. (DRMA) had $7.9M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Dermata Therapeutics, Inc. spend on research and development?

Dermata Therapeutics, Inc. (DRMA) invested $2.9M in research and development during fiscal year 2025.

How many shares does Dermata Therapeutics, Inc. have outstanding?

Dermata Therapeutics, Inc. (DRMA) had 4M shares outstanding as of fiscal year 2025.

What is Dermata Therapeutics, Inc.'s debt-to-equity ratio?

Dermata Therapeutics, Inc. (DRMA) had a debt-to-equity ratio of 0.26 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Dermata Therapeutics, Inc.'s return on assets (ROA)?

Dermata Therapeutics, Inc. (DRMA) had a return on assets of -96.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Dermata Therapeutics, Inc.'s P/E ratio?

Dermata Therapeutics, Inc. (DRMA) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $4.3M as of Oct 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Dermata Therapeutics, Inc.'s price-to-sales ratio?

Dermata Therapeutics, Inc. (DRMA) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $4.3M as of Oct 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Dermata Therapeutics, Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Dermata Therapeutics, Inc. (DRMA) held $7.5M in cash, cash equivalents and investments, and reported an operating cash outflow of $7.8M over that year. Dividing the one by the other, the reported balance equals about 12 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Dermata Therapeutics, Inc.'s Piotroski F-Score?

Dermata Therapeutics, Inc. (DRMA) has a Piotroski F-Score of 2 out of 5 computable signals; 4 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Dermata Therapeutics, Inc.'s earnings high quality?

Dermata Therapeutics, Inc. (DRMA) reported a net loss of $7.6M while operations used $7.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.